✓. Mean systolic blood pressure less than or equal to 150 mmHg and a mean diastolic blood pressure less than or equal to 95 mmHg
✓. Receiving ACEi and/or ARB therapy at an unchanged dose at or above the minimum trial dosage for at least 3 months prior to the first Screening visit and willing to maintain these doses throughout the treatment period
Exclusion criteria
✕. Females who are pregnant or breast feeding
✕. Organ transplant recipient, history of dialysis, or known non-diabetic renal disease other than benign cysts or anatomical variants
✕. History of New York Heart Association class III/IV heart failure
✕. Screening electrocardiogram showing acute and/or clinically significant findings including but not limited to ST depression
✕. History of any of the following events within 3 months prior to Screening: coronary artery bypass graft, cerebrovascular accident, myocardial infarction, transient ischemic attack, unstable angina, uncontrolled cardiac arrhythmia, atrial fibrillation, percutaneous coronary intervention, or vascular stent placement
What they're measuring
1
Measure: change from baseline in 24-hour urinary ACR for each arm compared with placebo
✕. History of anaphylactic or systemic allergic reaction to human, humanized, chimeric, or murine monoclonal antibodies
✕. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \>2.5 times the upper limit of normal; direct bilirubin above the upper limit of normal, or \>2.5 times the upper limit of normal in cases of documented Gilbert's syndrome